Oct 13, 2014

PsycheAnalytics announces first trial customer in primary care practice

PsycheAnalytics today announced it’s first customer trial in a primary care setting. “PSYCHeANALYTICS has found an opportunity to enter a very large market and provide a service that will make the treatment of chronic disease much more effective, less costly and more likely to improve the patient’s quality of life,” said David Haddick, CEO, “Our timing coincides with a major shift in the business model of healthcare that rewards efficiency and good outcomes over fee-for-service. We will facilitate the management of chronic disease without exacerbating the looming shortages of primary care physicians and mental health workers – a very valuable service for providers, payers and patients.”

Read More

Jul 7, 2014

PsycheAnalytics announces beta testing of prototype patient screening website

PsycheAnalytics has launched its first beta testing site for patient screening, available to select customers for testing purposes. “The fee-for-service reimbursement for each administration of PSYCHeDECISION is $49 according to Medicare guidelines that are followed by most insurers,” said David Haddick, CEO, “Our financial plan below is based on charging the healthcare providers $25 for each use. The net benefit of our service to the risk-sharing practice is more significant than the simple reimbursement for using our service, since we will enable savings in the total cost of managing chronically-ill patients. In our target market, our sales contracts will be based on the value of our contribution to the bottom line. We expect this will generate more usage of our service and higher revenue per account.”

Read More

Mar 1, 2014

PsycheAnalytics announces completion of prototype patient screening website

“Our approach to this market will begin with direct sales to Independent Practice Associations (IPAs), primary care and family medicine practices, Accountable Care Organizations and Patient-Centered Medical Homes,” said David Haddick, CEO, “We can work with their industry associations such as the California Association of Physician Groups (CAPG) to get our message to large numbers of practices with speed and efficiency.”

Read More

Jun 30, 2013

PsycheAnalytics announces launch of PsycheDecision

PsycheAnalytics today announced the company’s patent pending application for behavioral health decision support, PSYCHeDECISION™, enabling healthcare providers to assess the psychosocial and behavioral factors that afflict over 40% of patients with chronic diseases. Depression, anxiety, pain, sleep problems, alcohol misuse and other behavioral problems cause poor adherence to treatment and greatly increase the cost of care.

Read More



October 2014 | Washington, D.C.

CAPG Medicare Advantage Colloquium in Washington DC

Download Poster »


CUSTOMER SERVICES [+1] 415-577-7530

Our News & Events

Updated with our latest news, announcements and forthcoming events.

© 2015  PSYCHEANALYTICS   |   3881 Corina Way, Palo Alto, CA  |   USA   |   |   Tel.: USA [+1] 415-577-7530


Our Logo

Download High Res PNG »



Please contact

David Haddick, CEO

Tel.:  USA [+1] 415.577.7530